Recognition and management of myositis

Drugs

Volumn 54, Issue 1, 1997, Pages 39-49

  Cherin, Patrick ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISOLONE; PREDNISONE; TACROLIMUS;

BLADDER DISEASE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG EFFICACY; ELECTROMYOGRAPHY; FEVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; INFECTION; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE FUNCTION; MUSCLE WEAKNESS; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PLASMAPHERESIS; PNEUMONIA; POLYMYOSITIS; PROGNOSIS; RASH; REVIEW; STOMATITIS; TERATOGENICITY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0030839040     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00003     Document Type: Review

References (92)

1. Plotz PH, Rider LG, Targoff IR, et al. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122: 715-24
2. Medsger Jr TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48: 715-23
3. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7, 403-7
4. O'Leary PA, Waisman M. Dermatomyositis: a study of 40 cases. Arch Dermatol Syphilol 1940; 41: 1001-94
5. Fukunaga H, Osane M, Sakashita I, et al. Clinical and physiopathological findings in polymyositis. No To Shinkei (Japan) 1987; 39: 657-61
6. Miller FW, Seasonal, geographical, clinical and immunogenetic associations of the myositis-specific autoantibodies. In: Nervous system muscles and systemic diseases, Expansion Scientifique Française, Paris 1993; 123-7
7. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-t-RNA synthetase: a model for autoimmunity. Nature 1983; 304: 177-9
8. Bernstein RM, Morgan SH, Chapman J, et al. Anti JO-1 antibody: a market for myositis with interstitial lung disease. BMJ 1984; 289: 151-2
9. Miller FW, Love LA, Barbieri A, et al. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990; 81: 373-9
10. Iyer V, Lawton AR, Fenichel GM. T-cell subsets in polymyositis. Ann Neurol 1983; 13: 452-3
11. Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972; 286: 333-8
12. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. Ann Neurol 1984; 16: 193-208
13. Kissel JY, Mendell JR, Rammohan KW. Microvascular deposition of complement attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-34
14. Gayraud M, Tome F, Herson S, et al. Aspects histo-pathologiques des polymyosites et dermatomyosites. Corrélation avec le mode évolutif clinique. Ann Méd Interne 1989; 140: 445-8
15. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343-7
16. Cherin P, Herson S, Crevon MC, et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol 1996; 23: 1135-42
17. Cherin P, Herson S, Godeau P. Physiopathogenic des dermatomyosites et des polymyosites: mise au point. Ann Med Interne 1990; 141: 156-9
18. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-87
19. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis: a controlled clinical trial. Ann Intern Med 1980; 92: 365-9
20. Miller F, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380-2
21. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000
22. Mulder DW, Wilkelmann RK, Lambert EH, et al. Steroid therapy in patients with polymyositis and dermatomyositis. Ann Intern Med 1963; 58: 969-76
23. Pearson CM. Patterns of polymyositis and their responses to treatment. Ann Intern Med 1963; 59: 827-38
24. Winkelmann RK, Mulder DW, Lambert EH, et al. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone treated patients. Mayo Clin Proc 1968; 43: 545-56
25. Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982; 65: 280-300
26. Oddis CV, Medsger Jr TA. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositisdermatomyositis. J Rheumatol 1988; 15: 807-11
27. Carpenter JR, Bunch TW, Engel AG, et al. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977; 4: 207-14
28. Typhagne F, Revuz J, Touraine R. Le traitement des dermatomyosites: à propos de 16 cas. Ann Dermatol Venereol 1978; 105: 593-8
29. Etienne SD, Vandermcersch V, Chosidow O, et al. Paramètres pharmacocinétiques de la prednisone et de la prednisolone chez le volontaire sain. Ann Med Int 1990; 141: 507-11
30. Uchino M, Araki S, Yoshida O, et al. High single dose alternate day corticosteroid regimens in treatment of polymyositis. J Neurol 1985; 232: 175-8
31. Yanagisawa T, Sueishi M, Nawata Y, et al. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica 1983; 167: 47-51
32. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30: 328-34
33. Oddis CV, Hill P, Medsger Jr TA Functional outcome in a national cohort of polymyositis-dermatomyositis patients [abstract]. Arthritis Rheum 1992; 35: S88
34. Malaviya AN, Many A, Schwartz KS. Treatment of dermatomyositis with methotrexate. Lancet 1968; 11: 485-8
35. Arnett FC, Whelton JC, Zizic TM, et al. Methotrexate therapy in polymyositis. Ann Rheum Dis 1973; 32: 536-46
36. Metzger AL, Bohan A, Golberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182-9
37. Sokoloff MC, Goldberg LS, Pearson CM, Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet 1971; 1: 14-6
38. Mastaglia FL, Ojeda VJ. Inflammatory myopathics. Pt II. Ann Neurol 1985; 17: 317-23
39. Bohan A, Peter JB, Bowman RL, et al. A computer assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56: 255-86
40. Bunch TW. The therapy of polymyositis. Mt Sinai J Med 1988: 55: 483-6
41. Shiroki JB, Newkirk MM. Reversible lymphomas. N Engl J Med 1993; 329: 1657-8
42. Bunch TW. Prednisone and azathioprine for polymyositis: longterm follow-up. Arthritis Rheum 1981; 24: 45-8
43. Ramirez G, Asherson RA, Khamashta MA, et al. Adult onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Scmin Arthritis Rheum 1990; 20: 114-20
44. Fries JF, Sharp GC, McDevitt HO, et al. Cyclophosphamide therapy in systemic lupus crythematosus and polymyositis. Arthritis Rheum 1973; 16: 154-62
45. Haas DC. Treatment of polymyositis with immunosuppressive drugs. Neurology 1973; 23: 55-62
46. Bombardieri S, Hughes GRV, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; 1: 1138-9
47. Niakan E, Pitner SE, Whitaker JN, et al. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyos itis. Neurology 1980; 30: 286-91
48. Plowman PN, Stableforth DE. Dermatomyositis with fibrosing alveolitis: response to treatment with cyclophosphamide. Proc R Soc Med 1977; 70: 738-40
49. Al Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16: 1592-6
50. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 1225-8
51. Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28: 590-2
52. Bendtzen K, Tvede N, Andersen V, et al. Cyclosporin for polymyositis. Lancet 1984; I: 792-3
53. Ejstrup L. Severe dermatomyositis treated with cyclosporin A. Ann Rheum Dis 1986; 45: 612-3
54. The GHS, Jacobs P, Houben H. Cyclosporin in the treatment of intractable polymyositis. Arthritis Rheum 1985; 28: 1436-7
55. Gruhn WB, Diaz-Buxo JA. Cyclosporin treatment of steroid resistant interstitial pneumonitis associated with dermatopolymyositis. J Rheumatol 1987; 14: 1045-7
56. Girardin E, Dayer JM, Paunier L. Cyclosporin for juvenile dermatomyositis. J Pediatr 1988; 112: 165-6
57. Jones DW, Snaith ML, Isenberg DA. Cyclosporin treatment for intractable polymyositis. Arthritis Rheum 1987; 30: 959-60
58. Van Der Meer S, Imhof JW, Borleffs JCC. Cyclosporin for polymyositis [letter]. Ann Rheum Dis 1986; 45: 612
59. Zabel P, Leimenstoll G, Gross WL. Cyclosporin for acute dermatomyositis [letter]. Lancet 1984; I: 343
60. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1107-8
61. Jongen PJ, Joosten EM, Berden JH, et al. Cyclosporine therapy in chronic slowly progressive polymyositis - preliminary report of clinical results in three patients. Transplant Proc 1988; 20: 335-9
62. Alijotas J, Barquinero J, Ordi J, et al. Polymyositis and cyclosporin A [letter]. Ann Rheum Dis 1990; I: 66
63. Heckmatt J, Saunders C, Peters AM, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; I: 1063-6
64. Grau JM, Herrero C, Casademont J, et al. Cyclosporine A as first choice therapy in dermatomyositis. J Rheumatol 1994; 21: 381-2
65. Oddis CV, Caroll P, Abu-Elmagd K, et al. FK 506 in the treatment of polymyositis [abstract]. Arthritis Rheum 1994; 37 Suppl. 6: R19
66. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy: experience of 35 patients. Arch Neurol 1981; 38: 544-52
67. Bennington JL, Dau PC, Patients with polymyositis and dermatomyositis who undergo plasmapheresis therapy. Arch Neurol 1981; 38: 553-60
68. Aymard JP, Schooneman F, Gerard A, et al. Plasma therapy in polymyositis and dermatomyositis: Experience with nine patients. Plasma Ther Transfus Technol 1985; 6: 493-7
69. Herson S, Lok C, Gerard A, et al. Plasma exchange for dermatomyositis and polymyositis: retrospective study of 41 courses of plasma exchange. Plasma Ther Transfus Technol 1987; 8: 127-30
70. Kaye SA, Isenberg DA. Treatment of polymyositis and dermatomyositis. Br J Hosp Med 1994; 52: 463-8
71. Cherin P, Pourrat J, Bussel A, et al. Plasma exchange in polymyositis and dermatomyositis: analysis of 57 cases. Clin Exp Rheum 1995; 13: 270-1
72. Cherin P, Herson S, Wechsler B, et al. Intravenous immunoglobulin and polymyositis [letter]. Lancet 1990; II: 116
73. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-8
74. Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-72
75. Cherin P, Herson S. Indications of intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994; 57 Suppl.: 50-4
76. Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988; 259: 3269-71
77. Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1994; 1: 613-9
78. Cherin P, Piette JC, Wechsler B, et al. Intravenous gammaglobulin as first line therapy in polymyositis and dermatomyositis: a report of 11 cases. J Rheumatol 1994; 21: 1092-7
79. Engel WK, Lichter AS, Galdi AP, Polymyositis: remarkable response to total body irradiation [letter]. Lancet 1981; I: 658
80. Kelly JJ, Madoc-Jones H, Adelman LS, et al. Treatment of refractory polymyositis with total body irradiation [letter]. Neurology 1981; 31: 80
81. Hubbard WN, Walport MD, Halnan KE, et al. Remission from polymyositis after total body irradiation. BMJ 1982; 285: 1915-6
82. Schon F, Thomas PK, Sensnayake LF. Remission from polymyositis after total body irradiation [letter]. BMJ 1982; 285: 290
83. Engel WK, Lichter AS, Siddique T, Remarkable improvement sustained 1 to 2 years following total body irradiation (TBI): treatment of otherwise intractable adult polymyositis-dermatomyositis [abstract]. Neurology 1982; 32: A120
84. Morgan SH, Bernstein RM, Coppen J, et al. Total body irradiation and the course of polymyositis. Arthritis Rheum 1985; 28: 831-5
85. Aimart L, Sainty JM, Gastaut JL, et al. Un cas de dermatomyosite d'évolution favorable après irradiation corporelle totale [letter]. Presse Med 1987; 16: 1436
86. Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve 1988; 11: 120-3
87. Cherin P, Herson S, Coutellier A, et al. Failure of total body irradiation in polymyositis: report of three cases. Br J Rheumatol 1992; 31: 282-3
88. Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984; 10: 592-600
89. Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993; 20: 1340-4
90. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72: 225-35
91. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992, 19: 1385-9
92. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1944; 44: 1516-8